Thus, monoimmunotherapy with ICI (anti-PD-1 Nivolumab or Pembrolizumab and anti-PD-L1 Atezolizumab) is the second-line therapy of choice in metastatic NSCLC, without driver mutations, regardless of PD-L1 expression, which progresses after the first-line therapy with chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.